SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.  Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide.   SciBrunch will receive an upfront payment of $400 million and is eligible to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!